Albumin-Bilirubin Grade and Tumor Burden Score Predict Outcomes Among Patients with Intrahepatic Cholangiocarcinoma After Hepatic Resection: a Multi-Institutional Analysis
- PMID: 36652178
- DOI: 10.1007/s11605-023-05578-z
Albumin-Bilirubin Grade and Tumor Burden Score Predict Outcomes Among Patients with Intrahepatic Cholangiocarcinoma After Hepatic Resection: a Multi-Institutional Analysis
Abstract
Background: The prognostic role of tumor burden score (TBS) relative to albumin-bilirubin (ALBI) grade among patients undergoing curative-intent resection of ICC has not been examined.
Methods: We identified patients who underwent curative-intent resection for ICC between 1990 and 2017 from a multi-institutional database. Multivariable analysis was performed to assess the effect of TBS relative to ALBI grade on both short- and long-term outcomes.
Results: Among 724 patients, 360 (49.7%) patients had low TBS and low ALBI grade, 142 (19.6%) patients had low TBS and high ALBI grade, 138 (19.1%) patients had high TBS and low ALBI grade, and 84 patients (11.6%) had high TBS and high ALBI grade. Decreased tumor burden was associated with better long-term outcomes among patients with both low (5-year OS; low TBS vs. high TBS: 52.4% vs 21.4%; p < 0.001) and high ALBI grade (5-year OS; low TBS vs. high TBS: 40.7% vs 12.0%; p < 0.001). On multivariable analysis, higher ALBI grade was associated with greater odds of an extended hospital LOS (> 10 days) (OR 2.80, 95%CI 1.62-4.82; p < 0.001), perioperative transfusion (OR 2.04, 95%CI 1.25-3.36; p = 0.005), 90-day mortality (OR 2.56, 95%CI 1.12-5.81; p = 0.025), as well as a major complication (OR 1.99, 95%CI 1.13-3.49; p = 0.016) among patients with similar tumor burden. Of note, patients with high TBS and high ALBI grade had markedly worse overall survival compared with patients who had low TBS and low ALBI grade disease (HR 2.27; 95%CI 1.44-3.59; p < 0.001). Importantly, high TBS and high ALBI grade were strongly associated with both early recurrence (88.1%%) and 5-year risk of death (96.4%).
Conclusion: Both TBS (i.e., tumor morphology) and ALBI grade (i.e., hepatic function reserve) were strong predictors of outcomes among patients undergoing ICC resection. There was an interplay between TBS and ALBI grade relative to patient prognosis after hepatic resection of ICC with high ALBI grade predicting worse outcomes among ICC patients with different TBS.
Keywords: Albumin-bilirubin grade; Intrahepatic cholangiocarcinoma; Overall survival; Tumor burden.
© 2023. The Society for Surgery of the Alimentary Tract.
Similar articles
-
Prognostic utility of albumin-bilirubin grade for short- and long-term outcomes following hepatic resection for intrahepatic cholangiocarcinoma: A multi-institutional analysis of 706 patients.J Surg Oncol. 2019 Aug;120(2):206-213. doi: 10.1002/jso.25486. Epub 2019 Apr 25. J Surg Oncol. 2019. PMID: 31025380
-
Assessment of the Outcomes of Intrahepatic Cholangiocarcinoma After Ultrasound-Guided Percutaneous Microwave Ablation Based on Albumin-Bilirubin Grade.Cardiovasc Intervent Radiol. 2021 Feb;44(2):261-270. doi: 10.1007/s00270-020-02637-9. Epub 2020 Oct 14. Cardiovasc Intervent Radiol. 2021. PMID: 33057809
-
Tumor burden score as a new prognostic surrogate in patients with hepatocellular carcinoma undergoing radiofrequency ablation: role of albumin-bilirubin (ALBI) grade vs easy ALBI grade.Expert Rev Gastroenterol Hepatol. 2022 Sep;16(9):903-911. doi: 10.1080/17474124.2022.2117156. Epub 2022 Sep 1. Expert Rev Gastroenterol Hepatol. 2022. PMID: 35999514
-
Prognostic value of albumin-bilirubin grade in patients with cholangiocarcinoma: a systematic review and meta-analysis.BMC Gastroenterol. 2025 Jan 15;25(1):19. doi: 10.1186/s12876-025-03596-6. BMC Gastroenterol. 2025. PMID: 39815213 Free PMC article.
-
Prognostic role of preoperative albumin-bilirubin grade on patients with hepatocellular carcinoma after surgical resection: a systematic review and meta-analysis.Eur J Gastroenterol Hepatol. 2020 Jul;32(7):769-778. doi: 10.1097/MEG.0000000000001618. Eur J Gastroenterol Hepatol. 2020. PMID: 31834053
Cited by
-
Introducing and Validating the Multiphasic Evidential Decision-Making Matrix (MedMax) for Clinical Management in Patients with Intrahepatic Cholangiocarcinoma.Cancers (Basel). 2024 Dec 27;17(1):52. doi: 10.3390/cancers17010052. Cancers (Basel). 2024. PMID: 39796681 Free PMC article.
-
A New Prognostic Indicator for Biliary Tract Cancers: The ABIC Score.Curr Oncol. 2025 Mar 28;32(4):200. doi: 10.3390/curroncol32040200. Curr Oncol. 2025. PMID: 40277757 Free PMC article.
-
Tumor burden score and carcinoembryonic antigen predict outcomes in patients with intrahepatic cholangiocarcinoma following liver resection: a multi‑institutional analysis.BMC Cancer. 2024 Mar 20;24(1):358. doi: 10.1186/s12885-024-12091-2. BMC Cancer. 2024. PMID: 38509498 Free PMC article.
-
Construction and validation of a novel tumor morphology immune inflammatory nutritional score (TIIN score) for intrahepatic cholangiocarcinoma: a multicenter study.BMC Cancer. 2024 May 23;24(1):630. doi: 10.1186/s12885-024-12375-7. BMC Cancer. 2024. PMID: 38783240 Free PMC article.
-
International Validation and Refinement of Oncological Borderline Resectability Criteria for Hepatocellular Carcinoma Using Tumor Burden Score to Predict Survival.Ann Surg Open. 2025 Feb 26;6(1):e557. doi: 10.1097/AS9.0000000000000557. eCollection 2025 Mar. Ann Surg Open. 2025. PMID: 40134497 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical